DPP-4i, oral incretin-based therapy, is being used more frequently to treat type 2 diabetes mellitus (T2DM) as an add-on or substitute for other glucose-lowering medications, particularly sulphonylureas [11]. This evidence concerns the gene GCG and type 2 diabetes mellitus.